Scribd Logo
Upload

Welcome to Scribd!

  • Bismillah

    Uploaded by

    stroma januari
    16 views114 pages
    The document discusses setting target intraocular pressures (IOPs) for treating glaucoma and ocular hypertension. It describes how target IOP should be individualized based on factors like baseline IOP, disease severity, rate of progression, and response to treatment. The target is initially set as the level at which further progression is unlikely and is adjusted as needed based on disease progression. Treatment is initiated with the goal of reaching the target IOP to slow or stop further optic nerve damage.

    Original Description:

    Original Title

    bismillah

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The document discusses setting target intraocular pressures (IOPs) for treating glaucoma and ocular hypertension. It describes how target IOP should be individualized based on factors like baseline IOP, disease severity, rate of progression, and response to treatment. The target is initially set as the level at which further progression is unlikely and is adjusted as needed based on disease progression. Treatment is initiated with the goal of reaching the target IOP to slow or stop further optic nerve damage.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pptx, pdf, or txt
    16 views114 pages

    Bismillah

    Uploaded by

    stroma januari
    The document discusses setting target intraocular pressures (IOPs) for treating glaucoma and ocular hypertension. It describes how target IOP should be individualized based on factors like baseline IOP, disease severity, rate of progression, and response to treatment. The target is initially set as the level at which further progression is unlikely and is adjusted as needed based on disease progression. Treatment is initiated with the goal of reaching the target IOP to slow or stop further optic nerve damage.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pptx, pdf, or txt
    of 114

    Bismillah 

    The Indiana Bleb Appearance Grading Scale


    Aqueous Humor Dynamics

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 48.

    01/26/2024 5
    Aqueous Humor Production

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 48.

    01/26/2024 6
    Sources of Error with Goldmann Applanation
    Tonometry

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 99.

    01/26/2024 7
    Target IOP

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 492.

    01/26/2024 8
    Setting the Target IOP

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 496.

    01/26/2024 9
    Setting the Target IOP

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 496.

    01/26/2024 10
    IOP-lowering in
    Glaucoma and OHT

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 496.

    01/26/2024 11
    Initial Target Pressures

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 496.

    01/26/2024 12
    The Adrenergic Pathway and The Sites of Action
    of B-blockers

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 550.

    01/26/2024 13
    B-blockers Mechanisms

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 551.

    01/26/2024 14
    The Vascular Effects of Adrenergics and
    B-blockers

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 552.

    01/26/2024 15
    24-hour IOP Control

    From: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston J. Glaucoma 2nd Ed. Elsevier 2015: p. 553.

    01/26/2024 16
    Setting the Target IOP

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 131.

    01/26/2024 17
    Factors to consider when
    setting the target IOP

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 132.

    01/26/2024 18
    Considerations on Target IOP

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 132.

    01/26/2024 19
    Setting the Target IOP

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 133.

    01/26/2024 20
    Evaluation of Target IOP

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 134.

    01/26/2024 21
    Adjustment of Target IOP

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 135.

    01/26/2024 22
    Treatment Initiation

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 136.

    01/26/2024 23
    Considerations on 1st Choice
    Medical Treatment

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 136.

    01/26/2024 24
    Choosing Therapy

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 137.

    01/26/2024 25
    Therapeutical Algorithm
    in Topical Therapy

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 138.

    01/26/2024 26
    Year of 1st Clinical Use

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020: p. 141.

    01/26/2024 27
    PGA

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 28
    B-receptor Antagonists

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 29
    CAIs

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 30
    Alpha-2 Selective
    Adrenergic Agonists

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 31
    Rho Kinase Inhibitors

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 32
    Parasympathomimetics

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 33
    Osmotics

    From: European Glaucoma Society. Terminology and Guidelines for Glaucoma 5th Ed. Publicomm 2020.

    01/26/2024 34
    Outflow Pathway

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 18.

    01/26/2024 35
    Adrenergic Agents

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 140.

    01/26/2024 36
    ROCK Inhibitors
    Mechanism of Action

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 181.

    01/26/2024 37
    ROCK Activity

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 182.

    01/26/2024 38
    ROCK Inhibitors

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 183.

    01/26/2024 39
    ROCK Inhibitors

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 184.

    01/26/2024 40
    ROCK Inhibitors

    From: Kahook MY, Schuman JS. Chandler’ and Grant’s Glaucoma 6th Ed. Slack Incorporated 2021: p. 185.

    01/26/2024 41
    Progression from OHT to Manifest Glaucoma

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 344.

    01/26/2024 42
    Progression of
    Manifest Glaucoma

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 344.

    01/26/2024 43
    Medical vs
    Surgical Therapy

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 347.

    01/26/2024 44
    Medical vs
    Surgical Therapy

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 347.

    01/26/2024 45
    Bioavailability of
    Topical Medication

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 348.

    01/26/2024 46
    Bioavailability of
    Topical Medication

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 348.

    01/26/2024 47
    General Suggestions for
    Medical Treatment of Glaucoma

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 351.

    01/26/2024 48
    Initial Approach to
    Treatment of OAG

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 352.

    01/26/2024 49
    Theoretical Therapeutic
    Trial in One Eye

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 352.

    01/26/2024 50
    Effectiveness of a Drug

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 353.

    01/26/2024 51
    Adding Drugs

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 353.

    01/26/2024 52
    Maximum Effects

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 353..

    01/26/2024 53
    Effective or not?

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 353..

    01/26/2024 54
    Effective or not?

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 354.

    01/26/2024 55
    Increasing Drug Concentration

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 354..

    01/26/2024 56
    Increasing Ocular Contact Time

    From: Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. Mosby Elsevier 2009: p. 354

    01/26/2024 57
    Factors Affecting IOP

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 15.

    01/26/2024 58
    Rate of Progression

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 27.

    01/26/2024 59
    Target IOP

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 28.

    01/26/2024 60
    Set Target IOP Range

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 28.

    01/26/2024 61
    Efficacy and Dosing Frequency

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 36.

    01/26/2024 62
    Mechanism of Action

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 37.

    01/26/2024 63
    Medical Treatment
    Algorithm

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 39.

    01/26/2024 64
    Side Effects of
    Glaucoma Medications

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 99.

    01/26/2024 65
    Side Effects of
    Glaucoma Medications

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 100.

    01/26/2024 66
    Side Effects of
    Glaucoma Medications

    From: Asia-Pacific Glaucoma Guidelines Society. Asia-Pacific Glaucoma Guidelines 3rd Ed. Kugler Publications 2016: p. 101.

    01/26/2024 67
    Pneumatonometer

    From: Invest Ophthalmol Vis Sci. 2017 Jan;58(1): p. 204-210.

    01/26/2024 68
    Digital Schiotz Tonographer

    From: Invest Ophthalmol Vis Sci. 2017 Jan;58(1): p. 204-210.

    01/26/2024 69
    Pneumatonography

    From: Invest Ophthalmol Vis Sci. 2017 Jan;58(1): p. 204-210.

    01/26/2024 70
    Pneumatonography

    From: Invest Ophthalmol Vis Sci. 2017 Jan;58(1): p. 204-210.

    01/26/2024 71
    The Equation of Friedenwald

    From: Invest Ophthalmol Vis Sci. 2017 Jan;58(1): p. 204-210.

    01/26/2024 72
    Digital Schiotz Tonography

    From: Invest Ophthalmol Vis Sci. 2017 Jan;58(1): p. 204-210.

    01/26/2024 73
    Glaucoma vs OHT

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 3.

    01/26/2024 74
    OAG

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 4-6.

    01/26/2024 75
    Classification of Glaucoma

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 5.

    01/26/2024 76
    Classification of Glaucoma

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 6.

    01/26/2024 77
    Angle Closure

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 6-7.

    01/26/2024 78
    Aqueous Humor Flow

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 7.

    01/26/2024 79
    Push-Pull Mechanism

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 15.

    01/26/2024 80
    Physiologic Mechanisms

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 17.

    01/26/2024 81
    Suppression of Aqueous
    Humor Formation

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 18.

    01/26/2024 82
    Aqueous Humor Outflow

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 18.

    01/26/2024 83
    Trabecular Outflow

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 18.

    01/26/2024 84
    Uveoscleral Outflow

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 20.

    01/26/2024 85
    Aqueous Humor Dynamics

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 20-1.

    01/26/2024 86
    Tonography

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 22.

    01/26/2024 87
    Venomanometry

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 23.

    01/26/2024 88
    Factors that Affect IOP

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 25.

    01/26/2024 89
    Circadian Variation

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 25-6.

    01/26/2024 90
    Goldmann Applanation

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 26.

    01/26/2024 91
    Perkins Tonometer

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 27.

    01/26/2024 92
    Sources of Error in Tonometry

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 29.

    01/26/2024 93
    Tonometry and CCT

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 29.

    01/26/2024 94
    Pneumatonometer

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 30.

    01/26/2024 95
    Schiotz Tonometry

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020: p. 33.

    01/26/2024 96
    POAG –
    Primary vs Secondary

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 97
    POAG

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 98
    POAG – Risk Factors

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 99
    POAG – Risk Factors

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 100
    POAG – Risk Factors

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 101
    POAG – Risk Factors

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 102
    POAG – Risk Factors

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 103
    Glaucoma Suspect

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 104
    OHT

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 105
    Estimating Target Pressure

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 106
    Glaucoma Medications

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 107
    Glaucoma Medications

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 108
    Glaucoma Medications

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 109
    Glaucoma Medications

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 110
    Rho Kinase Inhibitors

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 111
    Rho Kinase Inhibitor

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 112
    Rho Kinase Inhibitor

    From: American Academy of Ophthalmology. Basic and Clinical Science Course 2020-2021 Section 10 Glaucoma. American Academy of Ophthalmology 2020.

    01/26/2024 113
    POAG and CCT

    From: American Academy of Ophthalmology. Preferred Practice Pattern.

    01/26/2024 114

    You might also like